These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
298 related items for PubMed ID: 22410254
1. Resistance to intravenous immunoglobulin (IVIG) in Kawasaki disease: no influence of different IVIG lot utilisation. Pagnini I, Marino A, Simonini G, Cimaz R. Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S170. PubMed ID: 22410254 [No Abstract] [Full Text] [Related]
2. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients. Sato S, Kawashima H, Kashiwagi Y, Hoshika A. Int J Rheum Dis; 2013 Apr; 16(2):168-72. PubMed ID: 23773640 [Abstract] [Full Text] [Related]
3. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance. Ogihara Y, Ogata S, Nomoto K, Ebato T, Sato K, Kokubo K, Kobayashi H, Ishii M. Pediatr Res; 2014 Sep; 76(3):287-93. PubMed ID: 24964229 [Abstract] [Full Text] [Related]
4. Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities. Loomba RS, Raskin A, Gudausky TM, Kirkpatrick E. Am J Ther; 2016 Sep; 23(6):e1293-e1299. PubMed ID: 25611359 [Abstract] [Full Text] [Related]
5. Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients. Wang Z, Xu Y, Zhou H, Wang Y, Li W, Lu Z, Jiang Z, Gu X, Zheng H, Zeng L, Huang P, Zhang L, Gu X. Cardiovasc Ther; 2020 Sep; 2020():3568608. PubMed ID: 32256707 [Abstract] [Full Text] [Related]
6. Role of the Egami score to predict immunoglobulin resistance in Kawasaki disease among a Western Mediterranean population. Sánchez-Manubens J, Antón J, Bou R, Iglesias E, Calzada-Hernandez J, Borlan S, Gimenez-Roca C, Rivera J, Kawasaki Disease in Catalonia Working Group. Rheumatol Int; 2016 Jul; 36(7):905-10. PubMed ID: 27215220 [Abstract] [Full Text] [Related]
7. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study. Nanishi E, Nishio H, Takada H, Yamamura K, Fukazawa M, Furuno K, Mizuno Y, Saigo K, Kadoya R, Ohbuchi N, Onoe Y, Yamashita H, Nakayama H, Hara T, Ohno T, Takahashi Y, Hatae K, Harada T, Shimose T, Kishimoto J, Ohga S, Hara T. J Am Heart Assoc; 2017 Jul 06; 6(7):. PubMed ID: 28684643 [Abstract] [Full Text] [Related]
8. Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease. Ye Q, Gong FQ, Shang SQ, Hu J. Clin Immunol; 2016 Oct 06; 171():25-31. PubMed ID: 27519954 [Abstract] [Full Text] [Related]
9. Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Lo MS, Newburger JW. Int J Rheum Dis; 2018 Jan 06; 21(1):64-69. PubMed ID: 29205910 [Abstract] [Full Text] [Related]
10. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis. Li X, Tang Y, Ding Y, Chen Y, Hou M, Sun L, Qian G, Qin L, Lv H. Eur J Pharmacol; 2021 May 15; 899():173985. PubMed ID: 33652059 [Abstract] [Full Text] [Related]
11. [Reply to questions regarding diagnosis and treatment of Kawasaki disease]. Wang HW. Zhonghua Er Ke Za Zhi; 2006 May 15; 44(5):337-8. PubMed ID: 16780708 [No Abstract] [Full Text] [Related]
12. [Current state of diagnosis and treatment of incomplete Kawasaki disease]. Zhang QY, Du JB. Zhonghua Er Ke Za Zhi; 2006 May 15; 44(5):339-41. PubMed ID: 16780709 [No Abstract] [Full Text] [Related]
13. Inability of Asian risk scoring systems to predict intravenous immunoglobulin resistance and coronary lesions in Kawasaki disease in an Italian cohort. Fabi M, Andreozzi L, Corinaldesi E, Bodnar T, Lami F, Cicero C, Tchana B, Landini C, Sprocati M, Bigucci B, Balsamo C, Sogno Valin P, Di Fazzio G, Iughetti L, Valletta E, Marchetti F, Donti A, Lanari M. Eur J Pediatr; 2019 Mar 15; 178(3):315-322. PubMed ID: 30499051 [Abstract] [Full Text] [Related]
14. The factors affecting the disease course in Kawasaki disease. Arslanoglu Aydin E, Ertugrul I, Bilginer Y, Batu ED, Sonmez HE, Demir S, Arici ZS, Sag E, Alehan D, Ozen S. Rheumatol Int; 2019 Aug 15; 39(8):1343-1349. PubMed ID: 31139951 [Abstract] [Full Text] [Related]
15. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease. Berdej-Szczot E, Małecka-Tendera E, Gawlik T, Firek-Pędras M, Szydłowski L, Gawlik A. Kardiol Pol; 2017 Aug 15; 75(3):261-266. PubMed ID: 27995598 [Abstract] [Full Text] [Related]
16. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases. Li X, Chen Y, Tang Y, Ding Y, Xu Q, Sun L, Qian W, Qian G, Qin L, Lv H. Eur J Pediatr; 2018 Aug 15; 177(8):1279-1292. PubMed ID: 29948255 [Abstract] [Full Text] [Related]
17. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin. Youn Y, Kim J, Hong YM, Sohn S. Pediatr Infect Dis J; 2016 Apr 15; 35(4):457-9. PubMed ID: 26673981 [Abstract] [Full Text] [Related]
18. Low risk of treatment resistance in Down syndrome with Kawasaki disease. Takatsuki S, Ogata S, Ishii M, Yokozawa M, Ono M, Fujiwara M, Ida H, Motomura H, Moriuchi H, Taketazu M, Kawamura Y, Kawano T, Izumi T, Shiono J, Tsuchiya S, Tsuchiya K, Goushi T, Ichida F, Saji T. Pediatr Int; 2017 Dec 15; 59(12):1236-1239. PubMed ID: 28960680 [Abstract] [Full Text] [Related]